# Fostering Efficacy of Anti - PD-1 - Treatment: Nivolumab Plus Radiotherapy in Advanced NSCLC

> **NCT03044626** · PHASE2 · COMPLETED · sponsor: **AIO-Studien-gGmbH** · enrollment: 101 (actual)

## Conditions studied

- Carcinoma，Non-Small-Cell Lung
- Metastatic Lung Cancer
- Nonsmall Cell Lung Cancer
- Lung Adenocarcinoma Metastatic
- Large Cell Lung Carcinoma Metastatic

## Interventions

- **DRUG:** Radiotherapy
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT03044626
- **Lead sponsor:** AIO-Studien-gGmbH
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-02-10
- **Primary completion:** 2020-12-31
- **Final completion:** 2020-12-31
- **Target enrollment:** 101 (ACTUAL)
- **Last updated:** 2021-01-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03044626

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03044626, "Fostering Efficacy of Anti - PD-1 - Treatment: Nivolumab Plus Radiotherapy in Advanced NSCLC". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03044626. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*